Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $396.4 million.

  • Praxis Precision Medicines' Liabilities and Shareholders Equity fell 477.3% to $396.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 5146.8%. This contributed to the annual value of $483.1 million for FY2024, which is 44931.32% up from last year.
  • Praxis Precision Medicines' Liabilities and Shareholders Equity amounted to $396.4 million in Q3 2025, which was down 477.3% from $452.8 million recorded in Q2 2025.
  • Praxis Precision Medicines' Liabilities and Shareholders Equity's 5-year high stood at $483.1 million during Q4 2024, with a 5-year trough of $87.9 million in Q4 2023.
  • In the last 4 years, Praxis Precision Medicines' Liabilities and Shareholders Equity had a median value of $239.5 million in 2022 and averaged $267.8 million.
  • Per our database at Business Quant, Praxis Precision Medicines' Liabilities and Shareholders Equity tumbled by 5892.22% in 2023 and then surged by 44931.32% in 2024.
  • Over the past 4 years, Praxis Precision Medicines' Liabilities and Shareholders Equity (Quarter) stood at $115.1 million in 2022, then decreased by 23.61% to $87.9 million in 2023, then skyrocketed by 449.31% to $483.1 million in 2024, then fell by 17.95% to $396.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $396.4 million for Q3 2025, versus $452.8 million for Q2 2025 and $478.7 million for Q1 2025.